Article Data

  • Views 36
  • Dowloads 1


Open Access

Lung replacement therapies for acute respiratory failure


1Department of Cardiothoracic Surgery, The First Hospital of Putian, Teaching Hospital, Fujian Medical University, Putian, Fujian Province, People’s Republic of China

DOI: 10.22514/SV121.102016.2 Vol.12,Issue S1,October 2016 pp.19-22

Published: 10 October 2016

*Corresponding Author(s): SHI-MIN YUAN E-mail:

PDF (272.18 kB)


Acute respiratory failure is one of the criti-cal conditions with an increased mortality. In order to reverse lung injury and reduce the mortality rate, several lung replace-ment therapies have been developed, in-cluding the extracorporeal membrane oxygenation, the intravascular oxygenator and carbon dioxide removal device, the in-travenous membrane oxygenator and the thoracic artificial lung. This article aims to present the properties, indications and ad-vantages of these devices.

Key words

artificial organs, extracorporeal membrane oxygenation, respiratory insuf-ficiency

Cite And Share

SHI-MIN YUAN. Lung replacement therapies for acute respiratory failure. Signa Vitae. 2016. 12(S1);19-22.


1. Suzuki T, Fukuda T, Ito T, Inoue Y, Cho Y, Kashima I. Continuous pulmonary perfusion during cardiopulmonary bypass prevents lung injury in infants. Ann Thorac Surg 2000;69(2):602-6.

2. Machin D, Allsager C. Principles of cardiopulmonary bypass. Contin Educ Anaesth Crit Care Pain 2006:6(5):176-81.

3. Friedman DF, Montenegro LM. Extracorporeal membrane oxygenation and cardiopulmonary bypass. In: Hillyer CD, Strauss RG, Luban NLC, eds. Handbook of Pediatric Transfusion Medicine. Amsterdam: Elsevier Inc. 2004;181-189.

4. Lewandowski K. Extracorporeal membrane oxygenation for severe acute respiratory failure. Crit Care 2000;4(3):156-68.

5. [homepage on the Internet]. West Columbia: Mid Carolina Internal Medicine Assoc.; 2004 [updated 19 Sep-tember 2016; cited 12 April 2016]. Available from: asp?articleid=1807#.V-B0RGTmAd4

6. Gattinoni L, Kolobow T, Tomlinson T, Iapichino G, Samaja M, White D, et al. Low-frequency positive pressure ventilation with extra-corporeal carbon dioxide removal (LFPPV-ECCO2R): an experimental study. Anesth Analg 1978;57(4):470-7.

7. Gattinoni L, Pesenti A, Caspani ML, Pelizzola A, Mascheroni D, Marcolin R, et al. The role of total static lung compliance in the man-agement of severe ARDS unresponsive to conventional treatment. Intensive Care Med 1984;10(3):121-6.

8. Terragni PP, Del Sorbo L, Mascia L, Urbino R, Martin EL, Birocco A, et al. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology 2009;111(4):826-35. doi: 10.1097/ALN.0b013e3181b764d2.

9. Bindslev L, Böhm C, Jolin A, Hambraeus Jonzon K, Olsson P, Ryniak S. Extracorporeal carbon dioxide removal performed with surface-heparinized equipment in patients with ARDS. Acta Anaesthesiol Scand Suppl 1991;95:125-30;130-1.

10. Conrad SA, Zwischenberger JB, Grier LR, Alpard SK, Bidani A. Total extracorporeal arteriovenous carbon dioxide removal in acute respiratory failure: a phase I clinical study. Intensive Care Med 2001 Aug;27(8):1340-51.

11. Hammainen P, Schersten H, Lemstrom K, Riise GC, Kukkonen S, Swärd K, et al. Usefulness of extracorporeal membrane oxygenation as a bridge to lung transplantation: a descriptive study. J Heart Lung Transplant 2011;30(1):103-7.

12. Hong X, Feng Z, Zhou G, Xu X. Extracorporeal membrane oxygenation as a support for TGA/IVS with low cardiac output syndrome and pulmonary hemorrhage. Rev Bras Cir Cardiovasc 2013;28(2):292-5.

13. Almond CS, Singh TP, Gauvreau K, Piercey GE, Fynn-Thompson F, Rycus PT, et al. Extracorporeal membrane oxygenation for bridge to heart transplantation among children in the United States: analysis of data from the Organ Procurement and Transplant Network and Extracorporeal Life Support Organization Registry. Circulation 2011;123(25):2975-84.

14. Chauhan S, Malik M, Malik V, Chauhan Y, Kiran U, Bisoi AK. Extra corporeal membrane oxygenation after pediatric cardiac surgery: a 10 year experience. Ann Card Anaesth 2011;14(1):19-24.

15. Finoti RG, Braile DM, Croti UA, Oliveira MA, Godoy MF, Leal JC, et al. Evaluation of infant membrane oxygenator in sheep. Rev Bras Cir Cardiovasc 2008;23(3):358-64.

16. Brogan TV, Thiagarajan RR, Rycus PT, Bartlett RH, Bratton SL. Extracorporeal membrane oxygenation in adults with severe respira-tory failure: a multi-center database. Intensive Care Med 2009;35(12):2105-14.

17. Merrill ED, Schoeneberg L, Sandesara P, Molitor-Kirsch E, O’Brien J Jr, Dai H, et al. Outcomes after prolonged extracorporeal mem-brane oxygenation support in children with cardiac disease–Extracorporeal Life Support Organization registry study. J Thorac Car-diovasc Surg 2014;148(2):582-8.

18. Mortensen JD, Berry G. Conceptual and design features of a practical, clinically effective intravenous mechanical blood oxygen/carbon dioxide exchange device (IVOX). Int J Artif Organs 1989;12(6):384-9.

19. Gasche Y, Romand JA, Prêtre R, Suter PM. IVOX in ARDS: respiratory effects and serious complications. Eur Respir J 1994;7(4):821-3.

20. Cox CS Jr, Zwischenberger JB, Kurusz M. Development and current status of a new intracorporeal membrane oxygenator (IVOX). Perfusion 1991;6(4):291-6.

21. Sim KM, Evans TW, Keogh BF. Clinical strategies in intravascular gas exchange. Artif Organs 1996;20(7):807-10.

22. Intravascular nano-bubbling oxygenator [internet]. Taipei, TW; 2015 [cited 12 April 2016]. Available from: http://www.freshpatents. com/Intravascular-nano-bubbling-oxygenator-dt20090409ptan20090093751.php

23. Kanamori T, Niwa M, Kawakami H, Mori Y, Nagaoka S, Haraya K, et al. Estimate of gas transfer rates of an intravascular membrane oxygenator. ASAIO J 2000;46(5):612-9.

24. Shen L, Xie W, Pang YW, Zhong W, Du QG, Yang YL. Evaluation of oxygen transfer rate of intravenous membrane oxygenator mod-ules. J Fudan Univ (Nat Sci) 2003;42(6):979-82.

25. Hattler BG, Reeder GD, Sawzik PJ, Lund LW, Walters FR, Shah AS, et al. Development of an intravenous membrane oxygenator: en-hanced intravenous gas exchange through convective mixing of blood around hollow fiber membranes. Artif Organs 1994;18(11):806-12.

26. Federspiel WJ, Hout MS, Hewitt TJ, Lund LW, Heinrich SA, Litwak P, et al. Development of a low flow resistance intravenous oxygen-ator. ASAIO J 1997;43(5):M725-30.

27. Kim KH, Choi JB, Kim GB. Gas transfer of an implatable artificial lung. Biomed Eng Res 2014;3(3):74-9.

28. Zwischenberger JB, Alpard SK. Artificial lungs: a new inspiration. Perfusion. 2002;17(4):253-68.

29. Thoracic artificial lung design (A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philoso-phy (Biomedical Engineering) in the University of Michigan) [internet]. Michigan: University of Michigan; 2012 [cited 12 April 2016]. Available from:

30. Cook KE, Perlman CE, Seipelt R, Backer CL, Mavroudis C, Mockrost LF. Hemodynamic and gas transfer properties of a compliant thoracic artificial lung. ASAIO J 2005;51(4):404-11.

31. Cook KE, Makarewicz AJ, Backer CL, Mockros LF, Przybylo HJ, Crawford SE, et al. Testing of an intrathoracic artificial lung in a pig model. ASAIO J 1996;42(5):M604-9.

32. Sato H, Griffith GW, Hall CM, Toomasian JM, Hirschl RB, Bartlett RH, et al. Seven-day artificial lung testing in an in-parallel configu-ration. Ann Thorac Surg 2007;84(3):988-94.

33. Eash HJ, Jones HM, Hattler BG, Federspiel WJ. Evaluation of plasma resistant hollow fiber membranes for artificial lungs. ASAIO J 2004;50(5):491-7.

34. Zhu A, Zhang J, Shen J. Preparation and anticoagulant property of phosphorylcholine‐terminated o‐benzoylchitosan derivative. J Appl Polymer Sci 2003;88(2):489-93.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) The Science Citation Index (SCI) is a citation index originally produced by the Institute for Scientific Information (ISI) and created by Eugene Garfield. It (Science Citation Index Expanded) covers more than 8,500 notable and significant journals, across 150 disciplines in science and technology, from 1900 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time